CA2308575A1 - Vecteurs d'expression inductible par hyperthermie utiles pour la therapie genique et procedes d'utilisation de ceux-ci - Google Patents
Vecteurs d'expression inductible par hyperthermie utiles pour la therapie genique et procedes d'utilisation de ceux-ci Download PDFInfo
- Publication number
- CA2308575A1 CA2308575A1 CA002308575A CA2308575A CA2308575A1 CA 2308575 A1 CA2308575 A1 CA 2308575A1 CA 002308575 A CA002308575 A CA 002308575A CA 2308575 A CA2308575 A CA 2308575A CA 2308575 A1 CA2308575 A1 CA 2308575A1
- Authority
- CA
- Canada
- Prior art keywords
- promoter
- expression
- cell
- expression construct
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne des procédés et des compositions utiles pour exprimer des transgènes dans des cellules cibles. L'invention concerne des produits de recombinaison d'expression utilisant un système d'amplification inductible pour diriger l'expression d'un gène thérapeutique ou d'un autre gène intéressant dans des cellules hôtes de mammifère, ainsi que des procédés utiles à cet effet. L'expression inductible des transgènes à des concentrations élevées dans des conditions physiologiques est la conséquence d'une induction provoquée par des conditions d'hyperthermie par rapport à la température de base des cellules hôtes.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6408897P | 1997-11-03 | 1997-11-03 | |
US60/064,088 | 1997-11-03 | ||
PCT/US1998/023387 WO1999023216A2 (fr) | 1997-11-03 | 1998-11-03 | Vecteurs d'expression inductible par hyperthermie utiles pour la therapie genique et procedes d'utilisation de ceux-ci |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2308575A1 true CA2308575A1 (fr) | 1999-05-14 |
Family
ID=22053477
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002308575A Abandoned CA2308575A1 (fr) | 1997-11-03 | 1998-11-03 | Vecteurs d'expression inductible par hyperthermie utiles pour la therapie genique et procedes d'utilisation de ceux-ci |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1029041A2 (fr) |
JP (1) | JP2001521740A (fr) |
KR (1) | KR20010031762A (fr) |
CN (1) | CN1299411A (fr) |
AU (1) | AU1377299A (fr) |
BR (1) | BR9813917A (fr) |
CA (1) | CA2308575A1 (fr) |
IL (1) | IL135943A0 (fr) |
WO (1) | WO1999023216A2 (fr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19951765A1 (de) * | 1999-10-27 | 2001-05-03 | Thomas Schweder | Wirts-Vektor-Systeme zur Überproduktion von thermolabilen Enzymen psychrophiler Organismen |
US6579522B1 (en) | 2000-06-27 | 2003-06-17 | Genvec, Inc. | Replication deficient adenoviral TNF vector |
US7285414B2 (en) | 2000-09-26 | 2007-10-23 | Emory University | Viruses targeted to hypoxic cells and tissues |
CA2423833C (fr) * | 2000-09-26 | 2011-02-22 | Emory University | Virus diriges sur des cellules et des tissus hypoxiques |
US20030086903A1 (en) | 2001-11-02 | 2003-05-08 | Genvec, Inc. | Therapeutic regimen for treating cancer |
EP1541674B9 (fr) | 2002-06-18 | 2011-09-14 | Eisai R&D Management Co., Ltd. | Adipocytes de culture primaire utilises en therapie genique |
AU2003278079A1 (en) * | 2002-10-14 | 2004-05-04 | Develogen Aktiengesellschaft Fur Entwicklungsbiologische Forschung | Proteins involved in the regulation of energy homeostasis |
JP2008048601A (ja) * | 2004-06-15 | 2008-03-06 | Nippon Kosei Kagaku Kenkyusho:Kk | 治療に有用な産物の生産法およびシステム |
EP1879622A2 (fr) * | 2005-05-03 | 2008-01-23 | Veterinärmedizinische Universität Wien | Capsules permeables |
RU2499599C2 (ru) * | 2007-09-28 | 2013-11-27 | Интрексон Корпорейшн | Конструкции терапевтического переключения генов и биореакторы для экспрессии биотерапевтических молекул и их применение |
CN103667345B (zh) * | 2013-12-02 | 2015-10-28 | 东南大学 | 一种抗肿瘤基因磁性复合纳米颗粒及制备方法 |
WO2017133175A1 (fr) * | 2016-02-04 | 2017-08-10 | Nanjing Legend Biotech Co., Ltd. | Cellules mammifères génétiquement modifiées pour thérapie anticancéreuse |
CN108913661A (zh) * | 2018-06-22 | 2018-11-30 | 安徽 | 一种人体研究用造血干细胞的制备和提取方法 |
CN114317588B (zh) * | 2020-09-29 | 2023-06-27 | 中国农业科学院生物技术研究所 | 一种作物高温响应型基因组精准甲基化调控回路 |
IT202200000788A1 (it) * | 2022-01-19 | 2023-07-19 | Bruno Cell S R L | Induzione sensibile alla temperatura del programma miogenico e/o adipogenico in cellule per la produzione di tessuto muscolare e/o adiposo |
CN116536349B (zh) * | 2023-05-22 | 2024-02-20 | 安徽农业大学 | 一种大豆GmMLP34基因在调控植物耐高温性上的应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3991770A (en) * | 1974-01-24 | 1976-11-16 | Leveen Harry H | Method for treating benign and malignant tumors utilizing radio frequency, electromagnetic radiation |
EP0299127A1 (fr) * | 1987-07-16 | 1989-01-18 | IntraCel Corporation | Procédé pour exprimer des gènes recombinants, stimulés par une protéine activatrice, exprimée par induction |
EP0455424A3 (en) * | 1990-05-02 | 1992-04-29 | Merck & Co. Inc. | Mammalian inducible promoter cascade system |
FR2717187B1 (fr) * | 1994-03-10 | 1996-05-31 | Transgene Sa | Usage combiné de deux cassettes d'expression pour la production d'une protéine d'intérêt. |
-
1998
- 1998-11-03 CA CA002308575A patent/CA2308575A1/fr not_active Abandoned
- 1998-11-03 KR KR1020007004827A patent/KR20010031762A/ko not_active Application Discontinuation
- 1998-11-03 WO PCT/US1998/023387 patent/WO1999023216A2/fr not_active Application Discontinuation
- 1998-11-03 EP EP98957538A patent/EP1029041A2/fr not_active Withdrawn
- 1998-11-03 JP JP2000519075A patent/JP2001521740A/ja active Pending
- 1998-11-03 IL IL13594398A patent/IL135943A0/xx unknown
- 1998-11-03 AU AU13772/99A patent/AU1377299A/en not_active Abandoned
- 1998-11-03 CN CN98812752A patent/CN1299411A/zh active Pending
- 1998-11-03 BR BR9813917-7A patent/BR9813917A/pt not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1029041A2 (fr) | 2000-08-23 |
CN1299411A (zh) | 2001-06-13 |
KR20010031762A (ko) | 2001-04-16 |
AU1377299A (en) | 1999-05-24 |
BR9813917A (pt) | 2001-10-30 |
JP2001521740A (ja) | 2001-11-13 |
WO1999023216A3 (fr) | 1999-08-05 |
WO1999023216A2 (fr) | 1999-05-14 |
IL135943A0 (en) | 2001-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2308575A1 (fr) | Vecteurs d'expression inductible par hyperthermie utiles pour la therapie genique et procedes d'utilisation de ceux-ci | |
EP0784693B1 (fr) | Vecteurs viraux pour la therapie genique | |
AU1755299A (en) | Vector for tissue-specific replication and gene expression | |
WO1994012629A9 (fr) | Vecteurs episomiques pour therapie genique | |
US20070244064A1 (en) | Methods and compositions to induce antitumor response | |
JPH10509880A (ja) | 組織特異的複製のためのベクター | |
JP2004501650A (ja) | 複製欠損アデノウイルスtnfベクター | |
JP2002506651A (ja) | 多重遺伝子ベクター | |
US6709858B1 (en) | Hyperthermic inducible expression vectors for gene therapy and methods of use thereof | |
US7056897B2 (en) | Inducible expression vectors and methods of use thereof | |
ES2268695T3 (es) | Adenovirus recombinantes defectivos con una gen iva2 inactivado. | |
US6451579B1 (en) | Regulated expression of recombinant proteins using RNA viruses | |
Tomita et al. | Gene therapy with transcription factor decoy oligonucleotides as a potential treatment for cardiovascular diseases | |
Kouraklis | Gene therapy for cancer | |
US7098191B2 (en) | Hyperthermic inducible expression vectors for gene therapy and methods of use thereof | |
WO1997016547A1 (fr) | VECTEURS D'EXPRESSION ADENOVIRAUX ANTISENS DU K-ras ET LEUR APPLICATION EN THERAPIE ANTICANCEREUSE | |
Palapattu et al. | GENE THERAPY FOR PROSTATE CANCER: New Perspectives on an Old Problem | |
MXPA00004293A (en) | Hyperthermic inducible expression vectors for gene therapy and methods of use thereof | |
WO2000022124A2 (fr) | Procedes et compositions permettant d'induire une reponse antitumorale | |
Clayman | Gene therapy for head and neck cancer | |
JP7406263B2 (ja) | 改変アデノウイルス及びこれを含む医薬 | |
JPH10127287A (ja) | 生体内でヒト遺伝子を導入するための新規アデノウィルス・ベクター | |
US5863794A (en) | SV40 viral vectors for targeted integration into cells | |
US20040146856A1 (en) | Anti-neoplastic viral agents | |
FR2737221A1 (fr) | Nouveaux vecteurs viraux pour la therapie genique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |